Race for approval of first oral GLP-1R drug in obesity intensifies with four in phase III trials: GlobalData Read more
NICE rejects second Alzheimer’s drug but opportunity remains for decision change: GlobalData Read more
Obesity drug tirzepatide approval in China strengthens market position amid GLP-1 agonist competition: GlobalData Read more